2AMJH
YSCHi001-A
General
Cell Line |
|
hPSCreg name | YSCHi001-A |
Cite as: | YSCHi001-A (RRID:CVCL_D0QC) |
Alternative name(s) |
2AMJH
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Last update | 18th May 2023 |
User feedback | |
Provider |
|
Generator | Severance Children’s Hospital (YSCH) |
External Databases |
|
BioSamples | SAMEA113447775 |
Cellosaurus | CVCL_D0QC |
Wikidata | Q123033962 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
Karyotyping
|
External Databases (Donor) |
|
BioSamples | SAMEA113447783 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | 세브란스병원 임상연구보호센터 |
Approval number | 4-2018-0021 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
Synonyms
|
Reprogramming method |
|
Vector type | Integrating |
Vector | Plasmid |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
G-banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.